Gyre Therapeutics, Inc.
GYREHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. At a $573.4M market cap, Gyre Therapeutics, Inc. ranks as a small-cap company within healthcare. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Market Cap
$573.4M
Beta
5.28
P/E (TTM)
—
P/E (Fwd)
98.50
EPS (TTM)
$-0.08
EPS (Fwd)
$0.06
ROE
-3.1%
ROA
1.0%
Cash
$49.8M
Total Debt
$823,000
Free CF
$9.6M
52W Change
-23.1%
Annual Financials
Cash vs Debt
With $49.8M in cash and $823K in debt, GYRE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $9.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -3.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $102.3M to $116.6M.
Gyre Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Gyre Therapeutics, Inc. and its sector.